Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled date : 2021 - 09 - 09 save search
Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
Published: 2021-09-09 (Crawled : 22:00) - biospace.com/
APLS G | $48.69 2.2% 2.16% 1.2M
|
Health Technology
|
| O: -0.88%
H: 2.83%
C: 0.94%
fda results phase 3 topline fda ide
VOR33 Granted U.S. FDA Fast Track Designation for AML
Published: 2021-09-09 (Crawled : 14:00) - biospace.com/
VOR | $1.89 3.85% 3.7% 210K
|
|
| O: 3.85%
H: 3.03%
C: -3.21%
fda fda fast track fast track granted fast track designation grant designation aml
FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction
Published: 2021-09-09 (Crawled : 14:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.61%
H: 0.29%
C: -5.25%
fda heart therapy breakthrough therapy granted grant designation
FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer
Published: 2021-09-09 (Crawled : 13:00) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: 1.9%
H: 3.69%
C: 0.07%
fda cancer device liver granted grant designation
FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma
Published: 2021-09-09 (Crawled : 12:00) - biospace.com/
SNGX | $0.4012 -1.13% -1.15% 450K
|
Health Technology
|
| O: 12.38%
H: 4.24%
C: -1.69%
treatment fda drug t-cell granted grant designation
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
Published: 2021-09-09 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -0.09%
H: 0.53%
C: -0.95%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -0.54%
H: 1.56%
C: -2.22%
new drug fda fda acceptance drug
FDA has declined Humanigen’s Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 Patients
Published: 2021-09-09 (Crawled : 09:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: -59.56%
H: 35.35%
C: 30.44%
covid fda lenzilumab merge authorized covid-19 emergency use authorization
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.